Chronic treatment of the bladder cancer cell lines RT112 and UMUC3 with the mTOR-inhibitor temsirolimus triggers resistance characterized by accelerated tumor growth and invasive behaviour. Here, MTOR is linked to urinary bladder carcinoma.